SEC Form 4 · accession 0001179110-19-001173

ABBOTT LABORATORIES · ABT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Senior Vice President

Period of report

Jan 30, 2019

Accepted (ET)

Feb 1, 2019 · 5:44 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000001800

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common shares without par value	Jan 30, 2019	M	46,017	$44.40	A	100,985	D
Common shares without par value	Jan 30, 2019	M	84,169	$38.40	A	185,154	D
Common shares without par value	Jan 30, 2019	M	83,951	$47.00	A	269,105	D
Common shares without par value	Jan 30, 2019	S	177,457	$70.00	D	91,648	D
Common shares without par value	Jan 31, 2019	M	62,600	$47.00	A	154,248	D
Common shares without par value	Jan 31, 2019	M	77,550	$38.40	A	231,798	D
Common shares without par value^F1	Jan 31, 2019	F	108,090	$71.68	D	111,301	D
Common shares without par value^F2	holding	—	—		—	22	I	Profit Sharing Trust
Common shares without par value^F3	holding	—	—		—	84,579	I	Jaime Contreras Marvan 2006 Living Trust
Common shares without par value^F4	holding	—	—		—	2,595	I	By Spouse
Common shares without par value^F5	holding	—	—		—	12,081	I	Living Trust (by spouse)

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option (right to buy)^F6	$44.40	Jan 30, 2019	M	46,017	D	Feb 17, 2018	Feb 16, 2027	Common Shares	46,017	92,032	D
Option (right to buy)^F6	$38.40	Jan 30, 2019	M	84,169	D	Feb 19, 2017	Feb 18, 2026	Common Shares	84,169	158,410	D
Option (right to buy)^F6	$47.00	Jan 30, 2019	M	83,951	D	Feb 20, 2016	Feb 19, 2025	Common Shares	83,951	62,600	D
Option (right to buy)^F6	$47.00	Jan 31, 2019	M	62,600	D	Feb 20, 2018	Feb 19, 2025	Common Shares	62,600	0	D
Option (right to buy)^F6	$38.40	Jan 31, 2019	M	77,550	D	Feb 19, 2018	Feb 18, 2026	Common Shares	77,550	80,860	D

F1Excludes 12,407 shares previously directly owned which were transferred to the Jaime Contreras Marvan 2006 Living Trust on September 21, 2018.
F2Balance in the Abbott Laboratories Stock Retirement Trust as of January 31, 2019.
F3Held in the Jaime Contreras Marvan 2006 Living Trust. The reporting person is sole trustee of the trust. The trust is revocable.
F4The reporting person disclaims beneficial ownership of all securities held by his spouse.
F5Held in spouse's living trust. The reporting person's spouse is sole trustee of the trust. The trust is revocable. The reporting person disclaims beneficial ownership of these securities.
F6Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).